Resmed Acquires Noctrix Health to Enter Restless Legs Syndrome Market
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The $2.1 billion all-cash deal will bring Avadel’s once-nightly oxybate, LUMRYZ, under Alkermes’ umbrella as it advances its orexin agonist pipeline for narcolepsy and other hypersomnolence disorders.
The insomnia medications Ambien and Ambien CR are now part of the company’s offerings following its acquisition from Sanofi.
ŌURA has acquired Sparta Science to enhance its Oura Teams platform, aiming to deliver scalable, data-driven health insights for enterprise clients, including healthcare and government organizations.
Read MoreThe Orlando-based company specializes in sleep apnea treatment, ventilators, oxygen, and other home medical equipment, expanding Owens & Minor’s reach in the home healthcare market.
Read MoreThe acquisition allows Sunrise to offer not only sleep diagnostics but also treat sleep issues.
Read MoreThe acquisition aims to improve the landscape of dental sleep medicine by addressing a long-standing challenge in the industry: medical billing.
Read MoreHealth Care Originals, a maker of cardiopulmonary wearable systems, has acquired Dawn Health’s virtual care platform, which offers cognitive behavioral therapy for insomnia.
Read MoreOpen Airway Dental Solutions Ltd, a Canadian medical technology company involved in the marketing and distribution of sleep dentistry-related products, acquired Australia-based oral appliance maker Oventus Medical Ltd earlier this year.
Read MoreThe acquisition allows Beacon to launch at-home sleep monitoring services for clinical trials via the integration of Dreem’s clinically-validated hardware with Beacon’s next-generation EEG analytics platform, according to Beacon.
Read MoreNox Health has closed the acquisition of Somryst, the only FDA-approved prescription digital therapeutic for adults with chronic insomnia, from Pear Therapeutics.
Read MoreNox Health Group is set to acquire Pear Therapeutics’ Somryst after being selected as the successful bidder at Pear’s bankruptcy auction last week.
Read MoreOura provides details on how the acquisition will help strengthen its position in the consumer wearables market.
Read MoreNatus will grow through the addition of the complete line of Micromed solutions to comprise an even stronger portfolio of products across EEG, PSG, EMG, and ICU monitoring.
Read MoreResApp has developed smartphone technology that can identify respiratory diseases based on cough analysis. Applications in the works include potentially screening for COVID-19 via cough sounds.
Read MoreThis transaction is expected to accelerate ProSomnus’ development and commercialization of its oral appliance therapy devices.
Read MoreThe acquisition of APIRx will significantly strengthen Incannex’s position with regard to cannabinoid and psychedelic treatment development.
Read MoreOwens & Minor’s two legacy segments will be replaced with two new segments: Patient Direct and Products & Healthcare Services.
Read More